J
Jakob Schöttle
Researcher at University of Cologne
Publications - 11
Citations - 1679
Jakob Schöttle is an academic researcher from University of Cologne. The author has contributed to research in topics: Lung cancer & Cancer. The author has an hindex of 10, co-authored 11 publications receiving 1528 citations. Previous affiliations of Jakob Schöttle include Max Planck Society.
Papers
More filters
Journal ArticleDOI
Frequent and Focal FGFR1 Amplification Associates with Therapeutically Tractable FGFR1 Dependency in Squamous Cell Lung Cancer
Jonathan Weiss,Martin L. Sos,Danila Seidel,Martin Peifer,Thomas Zander,Johannes M. Heuckmann,Roland T. Ullrich,Roopika Menon,Sebastian Maier,Alex Soltermann,Holger Moch,Patrick Wagener,Florian Fischer,Stefanie Heynck,Mirjam Koker,Jakob Schöttle,Frauke Leenders,Franziska Gabler,Ines Dabow,Silvia Querings,Lukas C. Heukamp,Hyatt Balke-Want,Sascha Ansén,Daniel Rauh,Ingelore Baessmann,Janine Altmüller,Zoe Wainer,Matthew Conron,Gavin M. Wright,Prudence A. Russell,Ben Solomon,Elisabeth Brambilla,Christian Brambilla,Philippe Lorimier,Steinar Sollberg,Odd Terje Brustugun,Walburga Engel-Riedel,Corinna Ludwig,Iver Petersen,Jörg Sänger,Joachim H. Clement,Harry J.M. Groen,Wim Timens,Hannie Sietsma,Erik Thunnissen,Egbert F. Smit,Daniëlle A.M. Heideman,Federico Cappuzzo,C. Ligorio,Stefania Damiani,Michael Hallek,Rameen Beroukhim,William Pao,Bert Klebl,Matthias Baumann,Reinhard Buettner,Karen Ernestus,Erich Stoelben,Jürgen Wolf,Peter Nürnberg,Peter Nürnberg,Sven Perner,Roman K. Thomas +62 more
TL;DR: F focal FGFR1 amplification is common in squamous cell lung cancer and associated with tumor growth and survival, suggesting that FGFR inhibitors may be a viable therapeutic option in this cohort of patients.
Journal ArticleDOI
CD74-NRG1 fusions in lung adenocarcinoma
Lynnette Fernandez-Cuesta,Dennis Plenker,Hirotaka Osada,Ruping Sun,Roopika Menon,Frauke Leenders,Sandra Ortiz-Cuaran,Martin Peifer,Marc Bos,Juliane Daßler,Florian Malchers,Jakob Schöttle,Jakob Schöttle,Wenzel Vogel,Ilona Dahmen,Mirjam Koker,Roland T. Ullrich,Roland T. Ullrich,Gavin M. Wright,Prudence A. Russell,Zoe Wainer,Benjamin Solomon,Elisabeth Brambilla,Hélène Nagy-Mignotte,Denis Moro-Sibilot,Christian Brambilla,Sylvie Lantuejoul,Janine Altmüller,Christian Becker,Peter Nürnberg,Johannes M. Heuckmann,Erich Stoelben,Iver Petersen,Joachim H. Clement,Jörg Sänger,Lucia Anna Muscarella,Annamaria la Torre,Vito Michele Fazio,Vito Michele Fazio,Idoya Lahortiga,Timothy Perera,Souichi Ogata,Marc Parade,Dirk Brehmer,Martin Vingron,Lukas C. Heukamp,Reinhard Buettner,Thomas Zander,Jürgen Wolf,Sven Perner,Sascha Ansén,Stefan A. Haas,Yasushi Yatabe,Roman K. Thomas +53 more
TL;DR: CD74-NRG1 gene fusions are activating genomic alterations in invasive mucinous adenocarcinomas and may offer a therapeutic opportunity for a lung tumor subtype with, so far, no effective treatment.
Journal ArticleDOI
Tumor VEGF:VEGFR2 autocrine feed-forward loop triggers angiogenesis in lung cancer
Sampurna Chatterjee,Lukas C. Heukamp,Maike Siobal,Jakob Schöttle,Caroline Wieczorek,Martin Peifer,Davide Frasca,Mirjam Koker,Katharina König,Lydia Meder,Daniel Rauh,Reinhard Buettner,Johanna Wolf,Rolf A. Brekken,Bernd Neumaier,Gerhard Christofori,Roman K. Thomas,Roland T. Ullrich +17 more
TL;DR: A tumor cell-autonomous VEGF:VEGFR2 feed-forward loop provides signal amplification required for the establishment of fully angiogenic tumors in lung cancer and interrupts this loop switches tumor cells from anAngiogenic to a proliferative phenotype that sensitizes tumor cells to MAPK inhibition.
Journal ArticleDOI
A framework for identification of actionable cancer genome dependencies in small cell lung cancer.
Martin L. Sos,Felix Dietlein,Felix Dietlein,Martin Peifer,Martin Peifer,Jakob Schöttle,Jakob Schöttle,Hyatt Balke-Want,Hyatt Balke-Want,Christian Müller,Christian Müller,Mirjam Koker,Mirjam Koker,André Richters,Stefanie Heynck,Stefanie Heynck,Florian Malchers,Florian Malchers,Johannes M. Heuckmann,Johannes M. Heuckmann,Danila Seidel,Danila Seidel,Patrick A. Eyers,Roland T. Ullrich,Andrey P. Antonchick,Viktor V. Vintonyak,Peter M. Schneider,Takashi Ninomiya,Herbert Waldmann,Reinhard Büttner,Daniel Rauh,Lukas C. Heukamp,Roman K. Thomas,Roman K. Thomas +33 more
TL;DR: This study suggests that a fraction of SCLC patients may benefit from therapeutic inhibition of Aurora B, and thorough chemical and genomic exploration of SclC cell lines may provide starting points for further development of rational targeted therapeutic intervention in this deadly tumor type.
Journal ArticleDOI
Erratum: Tumor VEGF:VEGFR2 autocrine feed-forward loop triggers angiogenesis in lung cancer (Journal of Clinical Investigation (2013) 123, 7 (3183) DOI:10.1172/JCI65385)
Sampurna Chatterjee,Lukas C. Heukamp,Maike Siobal,Jakob Schöttle,Caroline Wieczorek,Martin Peifer,Davide Frasca,Mirjam Koker,Katharina König,Lydia Meder,Daniel Rauh,Reinhard Buettner,Jürgen Wolf,Rolf A. Brekken,Bernd Neumaier,Gerhard Christofori,Roman K. Thomas,Roland T. Ullrich +17 more
TL;DR: A tumor cell-autonomous VEGF:VEGFR2 feed-forward loop provides signal amplification required for the establishment of fully angiogenic tumors in lung cancer and interrupts this loop switches tumor cells from anAngiogenic to a proliferative phenotype that sensitizes tumor cells to MAPK inhibition.